BIOA
BioAge Labs, Inc.
$22.16
-0.54 (-2.38%)
At close · Jul 16
Market Cap
$985.07M
Shares
44,452,734
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$22.16
Open$22.49
Day$21.65–22.70
52W$4.11–25.96
Avg vol 30d575K
Short int3.7M · 8.4% float · 4.0d
Short vol52%
Last earningsApr 21, 2026
DataSep 2024–Jul 2026
Filing10-Q · May 8
Up next
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed May 8, 2026
Equibles Rating
blended score · not investment advice
Overall
Neutral
SellHoldBuy
Technical
Neutral
Momentum
Very Strong
Sentiment
Neutral
Fundamentals
Strong
Quant / Vol
Very High
Market backdrop
VIX 16.7 · calm
Equity put/call 0.67
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
+42%
above
Price vs 50-day avg
+13%
above
RSI (14)
51
neutral
MACD trend
Negative
52-week position
83%
mid-range
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
+8%
trailing
6-month return
+17%
trailing
YTD return
+68%
this year
Relative strength
+8%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $20 › 200d $16 — 50d above 200d
Institutional flow
Distributing
6 of 145 funds reported for Jun 30 · net -138.7K sh shares · +1 new
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
8.42% of float · ▲ +87.9% MoM · 4.0 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
145 holders — near 1-yr high, broad support
Squeeze score
79
high risk · 0–100
Fundamentals
EPS growth
+66%
Y/Y
Free cash flow
$-82.3M
Balance sheet
$186.2M
net cash
Quant / Vol
risk profile
Volatility
85%
annualized · 1-yr
Max drawdown
−33%
past year
ATR
6.8%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Neutral
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
+42%
Bullish
Price vs 50-day avg
+13%
Bullish
RSI (14)
51
Neutral
MACD trend
Negative
Bearish
52-week position
83%
Neutral
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bearish · 2 of 6
Trend (MA cross)
No cross
50d $20 › 200d $16 — 50d above 200d
Institutional flow
Distributing
6 of 145 funds reported for Jun 30 · net -138.7K sh shares · +1 new
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
8.42% of float · ▲ +87.9% MoM · 4.0 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
145 holders — near 1-yr high, broad support
Price context
position in its 52-week range
52-wk low $4
Now $22 · 83%
52-wk high $26
vs 200-day avg +42%
vs 50-day avg +13%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Drug Manufacturers - Specialty & Generic — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
BIOA
this stock
BioAge Labs, Inc.
|
$985.07M | +67.5% | — | — | 8.4% |
|
TAK
Takeda Pharmaceutical Co Ltd
|
$54.77B | +7.3% | — | — | 0.2% |
|
GALDY
Galderma Group AG/ADR
|
$49.13B | +1.1% | — | — | 0.0% |
|
JHPCY
Jiangsu Hengrui Pharmaceuticals Co., Ltd./ADR
|
$45.13B | — | — | — | 0.0% |
|
HLN
Haleon plc
|
$44.48B | +0.0% | — | — | 0.3% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| BIOA | -11.0% | +8.2% | +17.3% | -9.6% | +67.5% |
| SPY | -0.1% | +0.1% | +9.0% | +0.5% | +10.1% |
| vs SPY | -10.8% | +8.1% | +8.3% | -10.1% | +57.4% |